Fluticasone propionate (Armonair Digihaler®) Drug Bulletin

December 2020

Nonproprietary Name	fluticasone propionate
Brand Name	Armonair Digihaler
Manufacturer	Teva
FDA Approval Date	January 27, 2020
Market Availability Date	Available
Indication	Maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older
Dosage Form	Inhalation powder
Dosage	55 mcg, 113 mcg, 232 mcg

CLINICAL CONSIDERATIONS[1]

- Armonair Digihaler is for oral inhalation and should not be used more than twice in a 24-hour period. It does not require priming and should not be used with a spacer or volume holding chamber.
- This product is contraindicated for use in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required and in patients with known severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to fluticasone propionate or any of the excipients.
- The recommended starting dose is based on asthma severity and current asthma therapy and strength. The maximum benefit may not be achieved for up to 2 weeks or longer after starting treatment and patients will experience a variable time to onset and degree of symptom relief.

SUGGESTED UTILIZATION MANAGEMENT

Anticipated Therapeutic Class Review (TCR) Placement	Glucocorticoids, Inhaled
Quantity Limit	1 inhaler/30 days
Duration of Approval	12 months
Drug to Disease Hard Edit	None

REFERENCES

1 Armonair Digihaler [package insert]. Parsippany, NJ; Teva; September 2020.